RNXT News & Events

RenovoRx announced that it has achieved a key milestone in its ongoing Phase III TIGeR-PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion in the first half of 2026, with final data expected in 2027. The trial is evaluating intra-arterial gemcitabine delivered via the company's RenovoCath device in locally advanced pancreatic cancer. "Reaching over 100 randomized patients marks an important milestone in our Phase III trial as we maintain strong momentum toward enrollment completion. We remain committed to completing the TIGeR-PaC trial and delivering final data in 2027," said Leesa Gentry, chief clinical officer of RenovoRx. "In parallel, select TIGeR-PaC cancer centers have begun using the TAMP therapy platform, enabled by the RenovoCath device, for targeted drug-delivery in the treatment of patients diagnosed with solid tumors."

RenovoRx announced the execution of definitive securities purchase agreements with institutional investors for an oversubscribed common stock and milestone warrant private placement which is expected to result in gross proceeds of approximately $10M to RenovoRx, before deducting offering expenses. The financing is being anchored by several leading, fundamentals-driven, life-science institutional investors. In addition, members of RenovoRx's executive management team and Board of Directors are investing in the private placement. Konik Capital Partners, a division of T.R. Winston & Company, is acting as the sole placement agent for the private placement. In connection with the private placement, RenovoRx will issue an aggregate of approximately 10,638,869 shares of common stock. Investors will pay a purchase price of $0.938 per share, and for that price will also receive milestone-based warrants to purchase an aggregate of approximately 5,319,434 shares of common stock, representing 50% warrant coverage. To comply with Nasdaq rules, RenovoRx executives and board members participating in the private placement will pay a higher purchase price of $1.029 per share and associated milestone warrant. The exercise price per share of the milestone warrants is $1.751, a 100% premium to the base per common share offering price. The warrants are exercisable immediately and will expire on the earlier to occur of 30 days following the Company's public announcement of the first fiscal quarter in which it achieves $1.5M in gross product revenue and March 30, 2029. The private placement was priced "at market" for purposes of Nasdaq Stock Exchange rules and is expected to close on March 20, 2026, subject to customary closing conditions.

RenovoRx announced continued commercial progress, with 12 U.S. cancer centers now utilizing the RenovoCath device. These 12 centers are in addition to those centers currently using RenovoCath as part of RenovoRx's ongoing Phase III trial. A total of 33 centers have requested access to RenovoCath, tripling the potential number of near-term commercial centers in RenovoRx's sales pipeline since the first quarter of 2025. The growing adoption reflects increasing clinical demand for RenovoCath as it becomes integrated into overall cancer treatment paradigms and sets the stage for Company revenue expansion in 2026.

RenovoRx announced that a clinical data abstract submission by cancer experts at Moffitt Cancer Center to the 2026 Society of Interventional Radiology, SIR, Annual Scientific Meeting has been accepted. The abstract, titled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer," was submitted by a multidisciplinary team of cancer experts, including Dr. Mustafa Al-Roubaie, an Interventional Radiologist at Moffitt Cancer Center and member of RenovoRx's Medical Advisory Board. The abstract explores the hypothesis, based on a review of metabolic response observations, that local, targeted intra-arterial delivery of chemotherapy using RenovoRx's patented TAMP therapy platform may help address the poor vascularity commonly associated with locally advanced pancreatic cancer. The abstract data further evaluates the potential role of metabolic imaging in evaluating therapeutic activity following targeted intra-arterial treatment in patients with refractory disease.